Advanced Oncotherapy: LIGHT – regulatory update

Hardman & Co
[shareaholic app="share_buttons" id_name="post_below_content"]

Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. The company is in the process of completing the complex assembly of its first full energy system, optimising, validating and verifying all aspects of this process. Meanwhile, it is liaising with the relevant regulators as part of the approval process. The FDA has requested some specific beam measurement data, which has added three months to the process but will generate important technical data that differentiates LIGHT and could be used in future marketing.

  • Strategy: Advanced Oncotherapy is developing a compact and modular PT system, which is affordable for the payor, financially attractive to the operator, and generating superior patient outcomes. AVO benefits from technology know-how developed by ADAM (CERN spin-off), and relies on a world-class supplier base.
  • Regulatory update: Although the FDA has requested some specific proton beam measurement data that will add up to a maximum of three months to the completion schedule, it highlights the progress that AVO has made with the FDA, and US regulatory approval now appears likely to come ahead of CE marking.
  • First LIGHT: Having been developing this highly technical and complex project for the past six years, the FDA’s request for additional data suggests that the first fully energy LIGHT system will now be completed by the end of 2Q’22. However, the market should be comforted by the progress made towards US approval.
  • Risks: To date, one of the key risks has been funding. However, AVO’s recent largest capital increase, coupled with alternative financing arrangements, have greatly diminished this risk. Regulatory risks have been reduced through ongoing dialogue with the FDA via the modular Q-Submission 510(k) process.
  • Investment summary: After some years in development Advanced Oncotherapy is nearing the finishing line with its first LIGHT system. However, the goal is to have a pipeline of installations to satisfy the pent-up demand and bring down the cost of PT. The current EV is lower than the quantum of investment to get LIGHT to where it is today. Additionally, the NPV of the cashflows from all potential sources of income from AVO’s evolving business model is currently 215p (161p fully diluted).

DOWNLOAD THE FULL REPORT

Share on:
Find more news, interviews, share price & company profile here for:

    Accesso Technology Group plc: What’s Driving Revenue and Resilience Amid Global Headwinds (Video)

    Richard Jeans explains how Accesso Technology Group (LON:ACSO) is managing global uncertainty while sharpening its strategic edge

    ICG Enterprise Trust: Mid-Teens Growth and 5.4x Returns, Why the Market Is Missing This (Video)

    Analyst Mark Thomas of Hardman & Co breaks down how ICGT Enterprise Trust continues to outperform

    NB Private Equity Partners Ltd: Long-term growth outlook (LON:NBPE)

    Explore insights from Hardman & Co’s analyst Mark Thomas on NB Private Equity Partners Ltd's recent performance and future growth prospects in this exclusive interview.

    Real Estate Credit Investments, Why Tough Markets Strengthen RECI’s Hand (Video)

    Mark Thomas explains how Real Estate Credit Investments (LON:RECI) is poised to benefit from macroeconomic uncertainty, not just survive it.

    NB Private Equity 2024 Results: Confirming the Model’s Long-term Growth Prospects (Video)

    Hardman & Co’s Mark Thomas explains why NB Private Equity Partners’ 2024 dip is masking a much stronger long-term growth story—one backed by impressive realisation multiples, stable EBITDA growth, and expanding investment opportunities.

      Search

      Search